40c will be a slow but solid build imo...updates around the efficacy / safety pharmacological & toxicology research should underpin that improvement as should, potentially the implications that will flow into the Phase 1 1st in human study down the track....so pleasingly the time horizon is in place..... balanced off against the opportunity cost implications in relation to the 12 month turn around for those trials to 'commence' means... imo anything else is a little too rosy a picture.
( subject to exceptional updates across the next 6 months of course - which is as likely as not...and Canary's' ability to generate additional and increasing interest for the investment case for NYR....which is obvious for the converted
)
that said - the final paragraph is extremely encouraging
great additional update
looking forward to that news flow across the second half of 2021
GLA
